1) Introduction Can be shortened focusing on complex interrelationship between CeD/IBD, hemorheology and coagulopathy and vascular risks. 2) Please mention what indices of hemorheological parameters will be used for data analysis and also please mention at what shear rate is WBV will be measured 3) Broad aims needs to be presented in primary and secondary objective section rather than telling what assessment you do. Like associating/correlating the rheological profiles with vascular risk factors or coagulopathy or immunological markers of the diseases etc. Other than comparing markers between case and control, Are you also trying to see the link between diseases/diseases specific parameters or cardiovascular complications with rheological and coagulopathy markers. If yes, this needs to be stated as objectives (primary or secondary). If yes, this needs to be also clarified in statistical analysis section.
4) BIOBANK:
Is it a single group biobank or multiple group can approach for the analysis of the sample. Nature of the biobank along with ethical aspects needs to be clarified. 5) 1 or 2 paragraphs of discussion will enhance the quality of the protocol paper (focusing on big picture of the trial, how the data helps to advance treatment or change clinical guidelines etc)
REVIEWER
Igor [Reply] We shortened and restructured the introduction to make it more consised and focused (Pgs 3-5, Lns 88-152).
2) Please mention what indices of hemorheological parameters will be used for data analysis and also please mention at what shear rate is WBV will be measured [Reply] Please, find all the hemorheological parameters measured in Supplementary material with a brief summary of methodological details. We adhere to the manual of use of the tools when performing the measurements. Viscosity is measured at 90 s-1 shear rate.
3) Broad aims need to be presented in primary and secondary objective section rather than telling what assessment you do. Like associating/correlating the rheological profiles with vascular risk factors or coagulopathy or immunological markers of the diseases etc. Other than comparing markers between case and control, Are you also trying to see the link between diseases/diseases specific parameters or cardiovascular complications with rheological and coagulopathy markers. If yes, this needs to be stated as objectives (primary or secondary). If yes, this needs to be also clarified in statistical analysis section.
[Reply] We rephrased the objectives (Pg 5, Lns 137-152) and the statistical section accordingly (Pgs 12-13, Lns 338-353).
4) BIOBANK:
Is it a single group biobank or multiple group can approach for the analysis of the sample. Nature of the biobank along with ethical aspects needs to be clarified.
[Reply] The Biobank receives samples from all the research projects run by the Centre for Translational Medicine (headquarter: University of Pécs). Frozen samples from each project (including ours) are deidentified, numbered, and kept in locked cabinets. Access to the cabinets containing biological material from HERMES is granted for the Principal Investigator of the study and those personnel involved in the maintenance of the facility, exclusively. Access to unauthorized personnel to the samples stored is strictly prohibited. The committee has approved the analysis pre-planned within the study protocol submitted for publication.
Other non-genetic investigations require modification of the ethical approval by submitting a modified study protocol to the board. Genetic investigations of the stored samples can only be performed if patients consented subsequently; however, the recent study protocol does not include any genetic studies.
5) 1 or 2 paragraphs of discussion will enhance the quality of the protocol paper (focusing on big picture of the trial, how the data helps to advance treatment or change clinical guidelines etc) [Reply] We agree. In line with this, we created a short discussion in the study protocol (Pgs 13-14, Lns 373-389).
[Authors' comment] We would like to thank Reviewer: 2 for the excellent comments, which have significantly improved the quality of our manuscript.
Reviewer: 3
Reviewer Name: Igor Dumic Institution and Country: Icahn School of Medicine at Mount Sinai, New York City, NY, USA Please state any competing interests or state 'None declared': None Please leave your comments for the authors below I have read with interest this study protocol. The study will attempt to address important questions and could provide valuable information in order to better understand the risks associated with hypercoagulability in patients with IBD and celiac disease. It is well written. I do have several concerns listed below. Those would need to be addressed before it is considered for publication.
Introduction: Please be more specific in the definition of celiac disease. It should be mentioned that celiac disease have gastrointestinal and extra intestinal manifestation and more should be elaborate about it's silent and atypical presentation.
[Reply] We added the information required to the 'Introduction' section (Pg 3, Lns 94-99).
The prevalence-it is higher in Scandinavian country and authors might consider describing the range of prevalence rather than just average worldwide.
[Reply] Indeed. Please, find the amended data based on the recent WGO guideline (Pg 3, Lns 95-96).
Lines 117 Line 135-a word is incomplete, please fix that [Reply] We completely rearranged the section mentioned.
Line 213-I would suggest excluding patient who are on anticoagulation for any reason, patient on anti-thrombotic therapy (aspirin, clopidogrel etc) and finally those who are on oral contraceptive pills and steroids. All of these are known to be associated with altered coagulation profile. People with recent (within one year VTE) and lupus patients should be excluded as well.
[Reply] Thank you for the thought-provoking comment. We rephrased the exclusion criteria and exclude those patients having a thrombotic event within one year of recruitment, taking vitamin K antagonists or antiplatelet drugs, and those with verified lupus (Pg 7, . Since there is a female predominance among celiac patients, and a significant fraction of the population is in childbearing age, the exclusion of patients using oral contraceptives may distort the generalizability of the population included. Exclusion of IBD cases receiving glucocorticoids may cause a distortion as well because we would lose a significant fraction of the active IBD cases, which will not allow us to perform the pre-planned subgroup analysis by disease activity. Based on this arguments, we do not think that the exclusion of these cases would be beneficial, but we will include these factors, as explanatory variables in the multivariate analysis (Pgs 12-13, Lns 344-346).
Line 266-267-GOLD standard for diagnosis of CD is small intestinal biopsy, and I believe that biopsy should be mandatory in all patients with suspected CD in order to confirm diagnosis before enrollment in the study [Reply] Indeed. We rephrased the inclusion criteria of celiac disease accordingly (Pg 7, Ln 179)
Line 268-271. I would refer authors to the following article : Hindryckx P, Levesque BG, Holvoet T, et al. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut 2018;67:61-69.
